Estás usando un navegador no soportado
Usar Internet Explorer está desaconsejado por problemas de seguridad. Para ver correctamente esta web, por favor use cualquier navegador moderno: Chrome, Firefox, Edge, Safari u otro de su elección.
En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias
FILTRAR POR:
543 ARTÍCULOS , VIENDO DEL 511 AL 525
GLP-1 Receptor Agonists in Neurodegeneration: Neurovascular Unit in the Spotlight
Monti G, Gomes Moreira D, Richner M, Mutsaers HAM, Ferreira N, Jan A.
Cells. 2022 Jun 25;11(13):2023. doi: 10.3390/cells11132023.
Inosine in Neurodegenerative Diseases: From the Bench to the Bedside
Basile MS, Bramanti P, Mazzon E.
Molecules. 2022 Jul 21;27(14):4644. doi: 10.3390/molecules27144644.
Targeting endoplasmic reticulum stress using natural products in neurological disorders
Jangra A, Verma M, Kumar D, Chandrika, Rachamalla M, Dey A, Dua K, Jha SK, Ojha S, Alexiou A, Kumar D, Jha NK.
Neurosci Biobehav Rev. 2022 Oct;141:104818. doi: 10.1016/j.neubiorev.2022.104818. Epub 2022 Aug 5.
Pradhan AU, Uwishema O, Onyeaka H, Adanur I, Dost B.
Brain Behav. 2022 Sep;12(9):e2740. doi: 10.1002/brb3.2740. Epub 2022 Aug 15.
Recent Advancements in CNS Acting Drugs: A Step Towards End of Illness
Javed MN, Pottoo FH, Naim MJ, Chawla PA.
CNS Neurol Disord Drug Targets. 2022;21(10):882-883. doi: 10.2174/187152732110220722112205.
Cell models for Alzheimer's and Parkinson's disease: At the interface of biology and drug discovery
Cetin S, Knez D, Gobec S, Kos J, Pišlar A.
Biomed Pharmacother. 2022 May;149:112924. doi: 10.1016/j.biopha.2022.112924. Epub 2022 Apr 8.
Alhowail A, Alsikhan R, Alsaud M, Aldubayan M, Rabbani SI.
Drug Des Devel Ther. 2022 Aug 31;16:2919-2931. doi: 10.2147/DDDT.S367229. eCollection 2022.
Naringenin: A prospective therapeutic agent for Alzheimer's and Parkinson's disease
Goyal A, Verma A, Dubey N, Raghav J, Agrawal A.
J Food Biochem. 2022 Dec;46(12):e14415. doi: 10.1111/jfbc.14415. Epub 2022 Sep 15.
Repurposing SGLT2 Inhibitors for Neurological Disorders: A Focus on the Autism Spectrum Disorder
Nakhal MM, Aburuz S, Sadek B, Akour A.
Molecules. 2022 Oct 23;27(21):7174. doi: 10.3390/molecules27217174.
Kopp KO, Glotfelty EJ, Li Y, Greig NH.
Pharmacol Res. 2022 Dec;186:106550. doi: 10.1016/j.phrs.2022.106550. Epub 2022 Nov 11.
Resolvins Lipid Mediators: Potential Therapeutic Targets in Alzheimer and Parkinson Disease
Anand S, Azam Ansari M, Kumaraswamy Sukrutha S, Alomary MN, Anwar Khan A, Elderdery AY.
Neuroscience. 2022 Dec 15;507:139-148. doi: 10.1016/j.neuroscience.2022.11.001. Epub 2022 Nov 11.
Applications of nanobodies in brain diseases
Zheng F, Pang Y, Li L, Pang Y, Zhang J, Wang X, Raes G.
Front Immunol. 2022 Nov 8;13:978513. doi: 10.3389/fimmu.2022.978513. eCollection 2022.
Neuroprotection and Non-Invasive Brain Stimulation: Facts or Fiction?
Guidetti M, Bertini A, Pirone F, Sala G, Signorelli P, Ferrarese C, Priori A, Bocci T.
Int J Mol Sci. 2022 Nov 9;23(22):13775. doi: 10.3390/ijms232213775.
Porphyromonas gingivalis, neuroinflammation and Alzheimer's disease
Owoyele PV, Malekzadeh S.
Niger J Physiol Sci. 2022 Dec 31;37(2):157-164. doi: 10.54548/njps.v37i2.1.
Mannan A, Singh TG, Singh V, Garg N, Kaur A, Singh M.
Curr Drug Targets. 2022;23(3):286-310. doi: 10.2174/1389450122666210707120256.
Actualización mensual Regístrese para recibir los avisos de actualización
Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.